Cadralazine

Cadralazine is a vasodilatory antihypertensive reportedly better-tolerated and longer-acting than hydralazine. It is useful as a second-line treatment in the management of hypertension.

Crystallized in acetone, melting point 160-162°C. pKa 6.0. UV max absorption: 248, 340m (ε22100, 2250). Solubility (mg/m1): water 1.3, hydrochloric acid 235.0, dimethyl sulfoxide 323.0, methanol 21.0, dioxane 18.6, chloroform 8.5, ether, benzene, and cyclohexane <0.1. Acute Toxicity LD50 rat, dog (mg/kg): 269, about 400 IV; 2060, >2000 oral. Acute toxicity LD50 rat (mg/kg): 700 intraperitoneal.

ISF;（Smith Mine) (Italy)

ChEBI: Cadralazine is an organic molecular entity.

Cadraten 21 cpr 20 mg;Cadraten 30 cpr 10 mg;Cadraten 30 cpr 15 mg;Cadratin;Cadrilan.

Cadralazine, a peripheral vasodilator, was introduced in 1989 for the treatment of arterial hypertension.In 1992, its association with serious side effects led to the refusal of registration in Norway. Animal experiments have demonstrated drug-related impairment of thyroid function as well as potential carcinogenicity and genotoxicity. It remains available for treatment of hypertension in Italy.